Related Experiment Video
Updated: May 29, 2026

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
Donepezil dosing strategies: pharmacokinetic considerations
Irving H Gomolin1, Candace Smith2, Thomas M Jeitner3
1Division of Geriatric Medicine and Clinical Pharmacology, Winthrop University Hospital, Mineola, NY; Department of Medicine, Stony Brook University, Stony Brook, NY.
Abstract:
Donepezil (Aricept) is a cholinesterase inhibitor approved for the treatment of Alzheimer's disease. Immediate release formulations of 5- and 10-mg tablets were approved by the Food and Drug Administration in the United States in 1996. In July 2010, the Food and Drug Administration approved a 23-mg sustained release (SR) formulation. The SR formulation may provide additional benefit to patients receiving 10 mg daily but the incidence of adverse reactions is increased. We derived plasma concentration profiles for higher dose immediate-release formulations (15 mg once daily, 10 mg twice daily, and 20 mg once daily) and for the profile anticipated to result from the 23-mg SR formulation. Our model predicts similar steady-state concentration profiles for 10 mg twice daily, 20 mg once daily, and 23 mg SR once daily. This provides the theoretical basis for incremental immediate release dose escalation to minimize the emergence of adverse reactions and the potential to offer a cost-effective alternative to the SR formulation with currently approved generic immediate release formulations.
Related Concept Videos
Dosage Regimens: Partial Pharmacokinetic Parameters
Drug Dosing: Geriatric Patients
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
Dosage Regimens: Designs and Approaches
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses